Agile Therapeutics: Rises on U.S. launch of its FDA-approved contraceptive patch

Agile Therapeutics

07/12/2020 13:42

** Drug developer's shares  AGRX.O  up 4% at $3.14 before
the bell, set to add to its YTD gain of 20% 
    ** Company announces the U.S. commercial launch of Twirla, a
non-daily, non-invasive contraceptive patch that was approved by
the U.S. FDA in February  urn:newsml:reuters.com:*:nGNX2XMl6D
    ** Twirla is the company's first product to be approved
after FDA turned down the marketing application for the patch in
2013 and 2017  urn:newsml:reuters.com:*:nL4N2AI2XW
    ** Analysts expect Twirla to be able to carve out a
meaningful share in the U.S. contraceptive market, based on its
milder side-effects and a potentially safer profile  urn:newsml:reuters.com:*:nL3N2AR3R2

 (Reporting by Ankur Banerjee in Bengaluru)